U.S. International Development Finance Corporation’s Post

#Adult_Vaccine Market Considerable Impact In Near Future 2023–2032 >> https://lnkd.in/eifGpkPE #Vaccine refers to a biological #preparation that includes inactive #antigen used to create an #immune response. Adult vaccines impart #immunity in the adult #population from various fatal infectious #diseases. Vaccination in #adults varies depending upon the age, #lifestyle, and health condition of the individual. #Adult vaccines are used to provide immunity against diphtheria, #influenza, hepatitis A & B, human papillomavirus (HPV), mumps, measles, #rubella And varicella {MMRV}, and other #infectious diseases. AstraZeneca Bharat Biotech CSL Limited Dynavax Technologies GSK ImmunoBiology Ltd Johnson & Johnson MedImmune Merck & Co., Inc. Novartis Pfizer Sanofi Pasteur MSD Serum Institute of India Pvt. Ltd. Adult Vaccine Alliance / Alliance Vaccins pour Adultes Adult Vaccine Access Coalition (AVAC) ADULT VACCINE ACCESS COALITION #healthcareindustry #pharmaceuticalindustry #vaccine #adult #immunity 

The study, titled ‘Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN) and ChAdOx1 nCoV-19 (COVISHIELD) in seronegative and s - https://lnkd.in/g-JNm7RK

Recently, three studies on SINOVAC BIOTECH LTD.'s Quadrivalent Influenza Vaccine (QIV) were published in the journals Vaccine and Vaccines. These papers demonstrate that the manufacturing process of the vaccine is both stable and reliable, confirm that its safety profile is comparable to that of an already licensed QIV, and reveal that the concomitant administration of QIV and PPSV23 in adults aged 60 and older results in non-inferior immunogenicity without increasing safety risks compared to separate administration. Join us as we explore the findings and implications of this important research. #influenza #vaccine #safety

GSK on Wednesday unveiled promising topline Phase III data for a combo regimen of its RSV vaccine Arexvy and shingles shot Shingrix, touting a comparable immunogenicity profile to the individual vaccines. The company did not provide specific data in its announcement, only noting that co-administering Arexvy with Shingrix resulted in a “non-inferior immune response” compared with inoculation with the vaccines at separate visits. The vaccine combo was also well-tolerated with an “acceptable” safety profile, according to GSK, though it’s not clear if there were more side effects after co-administration of the shots. GSK will use these Phase III data to build a regulatory case for the co-administration of Arexvy with Shingrix, which, if approved, could help the company shore up sales for these products. #biotech #biopharma #pharma #RSV #Shingles #vaccine

Annually, almost 2 billion vaccines are produced in 11 European countries. Having 12 high-end sites, Europe is at the forefront of next-generation vaccine R&D efforts. "#Vaccines are one of the greatest medical achievements of our time, saving 2-3 million lives globally each year by preventing #infectiousdiseases." Vaccines Europe, a specialized group within the EFPIA - European Federation of Pharmaceutical Industries and Associations, advocates for broader access to #immunization, to better protect #publichealth and reduce the burden on #healthservices. https://lnkd.in/eTnKK4Si

🚨 New #COVID19 Vaccine Update: The FDA has approved the Novavax® Vaccine, Adjuvanted (2024-2025 Formula) for individuals 12+! This updated formula targets the Omicron variant JN.1 and is designed for both unvaccinated individuals and those needing a booster. 💉 Unlike mRNA vaccines, Novavax uses a protein-based technology, offering another effective option against COVID-19. Full details on dosage schedules for various groups are available on the EUA fact sheets. Vaccines are expected to be available soon! https://lnkd.in/eKQtpcdF #Novavax #PublicHealth #VaccineUpdate #FightCOVID19

Today, PHAC launched the National Vaccine Catalogue (NVC), a bilingual and publicly accessible reference database of all vaccines authorized for use in Canada. The NVC provides a central repository for information to support standardized data collection, vaccine coverage surveillance, life cycle management of vaccines and immunization programming. Through strong collaborations and connections among data sources, the NVC will provide weekly updates that reflect the rapid changes to products, lot releases and shelf-life extensions. The data sources include: • Vaccine data from Health Canada – Drug Product Database • Vaccine lot and expiry date information from Health Canada’s Biologic and Radiopharmaceutical Drugs Directorate • Systematized Nomenclature of Medicine Clinical Terms, commonly known as SNOMED CT from Canada Health Infoway Check it out: https://ow.ly/UGiS50R4cJu

Today, PHAC launched the National Vaccine Catalogue (NVC), a bilingual and publicly accessible reference database of all vaccines authorized for use in Canada. The NVC provides a central repository for information to support standardized data collection, vaccine coverage surveillance, life cycle management of vaccines and immunization programming. Through strong collaborations and connections among data sources, the NVC will provide weekly updates that reflect the rapid changes to products, lot releases and shelf-life extensions. The data sources include: • Vaccine data from Health Canada – Drug Product Database • Vaccine lot and expiry date information from Health Canada’s Biologic and Radiopharmaceutical Drugs Directorate • Systematized Nomenclature of Medicine Clinical Terms, commonly known as SNOMED CT from Canada Health Infoway Check it out: https://ow.ly/UGiS50R4cJu

Opportunity: addressing the evidence gaps in mpox vaccine demand and access In June 2024 Gavi, the Vaccine Alliance’s Board approved an mpox vaccine programme. Gavi is now supporting vaccine delivery in affected countries in Africa and also preparing to set up a future stockpile. To inform these efforts we are now seeking for providers to assess the supply and demand generation needs for mpox vaccines in Gavi-eligible countries. Specifically, we are seeking answers to the following questions: Objective 1: On mpox vaccines and stockpiles: 🦠What is the demand for mpox vaccines and corresponding appropriate stockpile size for mpox vaccines in Gavi-eligible countries? 🦠What would be the associated potential public health impact of an mpox stockpile? Objective 2: On demand generation activities: 🦠Understand the enablers and drivers of vaccination uptake in priority populations in specific geographies (DRC and Burundi). 🦠Develop a prototype of a standardized demand strategy which can be adapted by countries to implement activities on-ground to drive vaccination uptake. 🦠Map the key stakeholders on the ground who can effectively engage with communities to drive vaccination uptake. Submit your bids by 29 November 2024 (intent to participate by 8 Nov) https://lnkd.in/eXixRePM #mpox #vaccines #rfp #globalhealth #research #implementationresearch

🚨 New #COVID19 Vaccine Update: The FDA has approved the Novavax® Vaccine, Adjuvanted (2024-2025 Formula) for individuals 12+! This updated formula targets the Omicron variant JN.1 and is designed for both unvaccinated individuals and those needing a booster. 💉 Unlike mRNA vaccines, Novavax uses a protein-based technology, offering another effective option against COVID-19. Full details on dosage schedules for various groups are available on the EUA fact sheets. Vaccines are expected to be available soon! More details from our partner VativoRx, LLC: https://lnkd.in/eKQtpcdF #Novavax #PublicHealth #VaccineUpdate #FightCOVID19